Business Description
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402681083
Share Class Description:
NKTR: Ordinary SharesCompare
Compare
Traded in other countries / regions
NKTR.USA0UNL.UKITH.GermanyNKTR.Mexico IPO Date
1994-05-03Description
Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.42 | |||||
| Equity-to-Asset | 0.23 | |||||
| Debt-to-Equity | 1.41 | |||||
| Debt-to-EBITDA | -0.77 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -14.32 | |||||
| Beneish M-Score | 5.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.9 | |||||
| 3-Year EBITDA Growth Rate | 16.5 | |||||
| 3-Year EPS without NRI Growth Rate | 30.5 | |||||
| 3-Year FCF Growth Rate | 17.2 | |||||
| 3-Year Book Growth Rate | -51.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 9.08 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -7.07 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.78 | |||||
| 9-Day RSI | 58.79 | |||||
| 14-Day RSI | 57.55 | |||||
| 6-1 Month Momentum % | 4.84 | |||||
| 12-1 Month Momentum % | 151.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.15 | |||||
| Quick Ratio | 4.9 | |||||
| Cash Ratio | 4.73 | |||||
| Days Inventory | 158.77 | |||||
| Days Sales Outstanding | 7.49 | |||||
| Days Payable | 59.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2 | |||||
| Shareholder Yield % | -5.29 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.22 | |||||
| Operating Margin % | -145.03 | |||||
| Net Margin % | -190.09 | |||||
| FCF Margin % | -188.25 | |||||
| ROE % | -127.63 | |||||
| ROA % | -42.69 | |||||
| ROIC % | -157.07 | |||||
| 3-Year ROIIC % | -72.75 | |||||
| ROC (Joel Greenblatt) % | -409.14 | |||||
| ROCE % | -42.11 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.95 | |||||
| PB Ratio | 3.26 | |||||
| Price-to-Tangible-Book | 3.26 | |||||
| EV-to-EBIT | -0.62 | |||||
| EV-to-EBITDA | -0.65 | |||||
| EV-to-Revenue | 1.02 | |||||
| EV-to-Forward-Revenue | 1.18 | |||||
| EV-to-FCF | -0.55 | |||||
| Price-to-Median-PS-Value | 0.29 | |||||
| Price-to-Net-Current-Asset-Value | 8.26 | |||||
| Price-to-Net-Cash | 35.13 | |||||
| Earnings Yield (Greenblatt) % | -161.29 | |||||
| FCF Yield % | -68.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NKTR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 93.157 | ||
| EPS (TTM) ($) | -0.9 | ||
| Beta | 0.78 | ||
| Volatility % | 75.47 | ||
| 14-Day RSI | 57.55 | ||
| 14-Day ATR ($) | 0.08818 | ||
| 20-Day SMA ($) | 1.2985 | ||
| 12-1 Month Momentum % | 151.89 | ||
| 52-Week Range ($) | 0.4126 - 1.928 | ||
| Shares Outstanding (Mil) | 184.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nektar Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nektar Therapeutics Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(NKTR)'s stock price today?
The current price of NKTR is $1.40. The 52 week high of NKTR is $1.93 and 52 week low is $0.41.
When is next earnings date of Nektar Therapeutics(NKTR)?
The next earnings date of Nektar Therapeutics(NKTR) is 2024-11-07 Est..
Does Nektar Therapeutics(NKTR) pay dividends? If so, how much?
Nektar Therapeutics(NKTR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers